Cargando…

Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth

Activating transcription factor-5 (ATF5) is an anti-apoptotic factor and has been implicated in enhancing the survival of cancer cells under stress and in regulating the autophagy process. Targeting ATF5 in anticancer therapy may be particularly attractive because of its differential role in cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Shmuel, Sarit, Rashed, Rola, Rostoker, Ran, Isakov, Elina, Shen-Orr, Zila, LeRoith, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519529/
https://www.ncbi.nlm.nih.gov/pubmed/28785242
http://dx.doi.org/10.3389/fendo.2017.00173
_version_ 1783251633351688192
author Ben-Shmuel, Sarit
Rashed, Rola
Rostoker, Ran
Isakov, Elina
Shen-Orr, Zila
LeRoith, Derek
author_facet Ben-Shmuel, Sarit
Rashed, Rola
Rostoker, Ran
Isakov, Elina
Shen-Orr, Zila
LeRoith, Derek
author_sort Ben-Shmuel, Sarit
collection PubMed
description Activating transcription factor-5 (ATF5) is an anti-apoptotic factor and has been implicated in enhancing the survival of cancer cells under stress and in regulating the autophagy process. Targeting ATF5 in anticancer therapy may be particularly attractive because of its differential role in cancer cells than in non-transformed cells, thus allowing specificity of the treatment. Using the delivery of short hairpin RNA vectors into the Mvt1 and Met1 cell lines, we tested the role of ATF5 in the development of mammary tumors in vivo and in regulating proliferation and migration of these cells in vitro. In this study, we demonstrate that knockdown of ATF5 (ATF5-KD) in both cell lines results in a decreased tumor volume and weight, as well as in a reduced proliferation rate and migratory potential of the cells. In addition, ATF5-KD led to an increased autophagy flux and a shift in the sub-populations comprising Mvt1 cells from the aggressive CD24-positive cells toward less aggressive CD24-negative cells. Taken together, these findings suggest that ATF5 plays an important role in enhancing mammary tumor cells overall aggressiveness and in promoting mammary tumor growth and emphasize the possible benefit of anti-ATF5 therapy in breast cancer patients, particularly, against tumors characterized with the positive expression of cell surface CD24.
format Online
Article
Text
id pubmed-5519529
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55195292017-08-07 Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth Ben-Shmuel, Sarit Rashed, Rola Rostoker, Ran Isakov, Elina Shen-Orr, Zila LeRoith, Derek Front Endocrinol (Lausanne) Endocrinology Activating transcription factor-5 (ATF5) is an anti-apoptotic factor and has been implicated in enhancing the survival of cancer cells under stress and in regulating the autophagy process. Targeting ATF5 in anticancer therapy may be particularly attractive because of its differential role in cancer cells than in non-transformed cells, thus allowing specificity of the treatment. Using the delivery of short hairpin RNA vectors into the Mvt1 and Met1 cell lines, we tested the role of ATF5 in the development of mammary tumors in vivo and in regulating proliferation and migration of these cells in vitro. In this study, we demonstrate that knockdown of ATF5 (ATF5-KD) in both cell lines results in a decreased tumor volume and weight, as well as in a reduced proliferation rate and migratory potential of the cells. In addition, ATF5-KD led to an increased autophagy flux and a shift in the sub-populations comprising Mvt1 cells from the aggressive CD24-positive cells toward less aggressive CD24-negative cells. Taken together, these findings suggest that ATF5 plays an important role in enhancing mammary tumor cells overall aggressiveness and in promoting mammary tumor growth and emphasize the possible benefit of anti-ATF5 therapy in breast cancer patients, particularly, against tumors characterized with the positive expression of cell surface CD24. Frontiers Media S.A. 2017-07-21 /pmc/articles/PMC5519529/ /pubmed/28785242 http://dx.doi.org/10.3389/fendo.2017.00173 Text en Copyright © 2017 Ben-Shmuel, Rashed, Rostoker, Isakov, Shen-Orr and LeRoith. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Ben-Shmuel, Sarit
Rashed, Rola
Rostoker, Ran
Isakov, Elina
Shen-Orr, Zila
LeRoith, Derek
Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title_full Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title_fullStr Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title_full_unstemmed Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title_short Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth
title_sort activating transcription factor-5 knockdown reduces aggressiveness of mammary tumor cells and attenuates mammary tumor growth
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519529/
https://www.ncbi.nlm.nih.gov/pubmed/28785242
http://dx.doi.org/10.3389/fendo.2017.00173
work_keys_str_mv AT benshmuelsarit activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth
AT rashedrola activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth
AT rostokerran activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth
AT isakovelina activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth
AT shenorrzila activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth
AT leroithderek activatingtranscriptionfactor5knockdownreducesaggressivenessofmammarytumorcellsandattenuatesmammarytumorgrowth